thebench.bio #1 Ecosystem for the Bio-Tech Industry

Life Sciences Daily Summary

Life Sciences Daily Summary: What Happened on November 8, 2026

Semaglutide lowered exercise heart pressures in an 81-person trial

The FDA granted uniQure’s Huntington’s gene therapy priority review. A Senate discussion draft proposed new rules for software medical devices.

  • Updated
  • Read from 6 articles, 4 publications
  • N T F P

Today in brief

In an 81-person trial, semaglutide lowered heart-filling pressure during exercise in people with obesity-related heart failure after 52 weeks.1 The FDA granted priority review to uniQure’s application for its Huntington’s gene therapy, AMT-130.2

Senator Bill Cassidy released a discussion draft proposing changes to FDA review of software-based and integrated medical devices.3

Semaglutide lowered exercise heart pressures in an obesity-related heart-failure trial

Semaglutide lowered exercise heart pressure more than placebo in a randomized trial of 81 people with obesity and heart failure after 52 weeks.1 Average exercise pulmonary artery wedge pressure fell 9.8 mmHg with semaglutide and rose 0.9 mmHg with placebo, for an estimated between-group difference of 10.6 mmHg.1

Hemodynamic remission, meaning an improvement in heart pressures, occurred in 53.7% of participants receiving semaglutide and 7.4% receiving placebo.1 In a separate, prespecified magnetic resonance substudy of 49 participants, semaglutide improved measures of heart structure and function after 52 weeks.4 The study authors said those changes may help explain the drug’s effects on heart pressures.4

FDA grants uniQure’s Huntington’s gene therapy priority review

The FDA accepted uniQure’s application for AMT-130 and granted it priority review.2 The therapy uses an AAV5 vector to deliver an artificial microRNA designed to silence the Huntingtin gene.2

AMT-130 requires neurosurgery. Some patients experienced neuroinflammation.2

Senate draft proposes changes to FDA review of software medical devices

Senator Bill Cassidy released a discussion draft of the PATIENT AI Act, which proposes changes to FDA review of software-based and integrated medical devices.3 The draft would direct the FDA to create risk-based premarket review for software devices and allow certain plans for reviewing later changes.3

It proposes voluntary preliminary review of integrated-device components, while requiring the complete device to follow an existing authorization pathway.3 The draft would create accredited third-party review and a voluntary pilot to update postmarket surveillance.3 The proposal’s authors said it could duplicate existing FDA processes, and its practical value would depend on implementation.3

Also worth knowing

  • P

    UK Research and Innovation will provide more than £52 million to five hubs developing early-detection technologies. Industry partners will add £37.5 million in cash and in-kind support.5

  • P

    MedPharm appointed Jason Mieding chief operating officer and head of its semisolid manufacturing site, creating a new role.6